The Roadmap to Personalized Medicine
نویسندگان
چکیده
منابع مشابه
Roadmap to personalized medicine
Standard clinical protocols and the concept "one drug fits all" that are currently used to treat illness in many cases are not effective, and strikingly so in the treatment of cancer, where 75% of therapeutic schemes are ineffective. The concept of personalized medicine is that the treatment of the disease is designed on the basis of the individual needs of each patient and the factors that inf...
متن کاملBreast Cancer Detection: Current Methods and Roadmap to Personalized Medicine
Breast cancer is characterized by uncontrolled growth of malignant cells in the mammary epithelial tissue. The etiology of breast cancer is poorly understood and in spite of substantial therapeutic advances, breast cancer treatment remains as an unsolved issue. Though few genetic markers for hereditary breast cancer have been identified, the etiology of sporadic breast cancer remains poorly und...
متن کاملThe path to personalized medicine.
n engl j med 363;4 nejm.org july 22, 2010 301 to human illness, identified genetic variability in patients’ responses to dozens of treatments, and begun to target the molecular causes of some diseases. In addition, scientists are developing and using diagnostic tests based on genetics or other molecular mechanisms to better predict patients’ responses to targeted therapy. The challenge is to de...
متن کاملIntroduction to Personalized Medicine
Readers may have noticed a new healthcare catchphrase gracing magazine covers and even the front page of the New York Times: “personalized medicine.”1 But what does it mean and how will it change healthcare? According to the President’s Council of Advisors on Science and Technology, ‘Personalized medicine refers to the tailoring of medical treatment to the individual characteristics of each pat...
متن کاملFrom Evidence-based Medicine to Personalized Medicine
elderly population. The subgroup analysis of the NSABP C-07 trial showed a trend towards better disease-free survival in patients younger than age 70 (hazard ratio, 0.80; 95% confidence interval, 0.68 to 0.95; P = 0.013), but no positive effect was evident in older patients with the addition of oxaliplatin to the FL regimen [10]. Even the NCCN guideline recommended that the oxaliplatinbased reg...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical and Translational Science
سال: 2008
ISSN: 1752-8054,1752-8062
DOI: 10.1111/j.1752-8062.2008.00045.x